{
    "root": "2fc6230c-73db-4b01-e063-6294a90ae208",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Formoterol Fumarate Inhalation Solution",
    "value": "20250307",
    "ingredients": [
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31404"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "FORMOTEROL FUMARATE",
            "code": "W34SHF8J2K",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31633"
        }
    ],
    "indications": {
        "text": "formoterol fumarate inhalation solution long-acting beta 2 -adrenergic agonist ( beta 2 -agonist ) indicated : long-term , twice daily ( morning evening ) maintenance treatment bronchoconstriction patients chronic obstructive pulmonary disease ( chronic obstructive pulmonary disease ) , including chronic bronchitis emphysema . ( 1.1 ) important limitations : formoterol fumarate inhalation solution indicated treat acute deteriorations chronic obstructive pulmonary disease . ( 1.2 , 5.2 ) formoterol fumarate inhalation solution indicated treat asthma . ( 1.2 )",
        "doid_entities": [
            {
                "text": "chronic obstructive pulmonary disease (DOID:3083)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3083"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "chronic bronchitis (DOID:6132)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6132"
            },
            {
                "text": "asthma (DOID:2841)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2841"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute deteriorations chronic",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_454831"
            },
            {
                "disease": "chronic bronchitis emphysema",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_98255"
            }
        ]
    },
    "contraindications": {
        "text": "recommended dose formoterol fumarate inhalation solution one 20 mcg unit-dose vial administered twice daily ( morning evening ) nebulization . total daily dose greater 40 mcg recommended . formoterol fumarate inhalation solution administered orally inhaled route via standard jet nebulizer connected air compressor . safety efficacy formoterol fumarate inhalation solution established trials administered using pari-lc plus\u00ae nebulizer ( facemask mouthpiece ) proneb\u00ae ultra compressor . safety efficacy formoterol fumarate inhalation solution delivered non-compressor based nebulizer systems established . formoterol fumarate inhalation solution always stored foil pouch , removed immediately . contents partially used container discarded . recommended maintenance treatment regimen fails provide usual response , medical advice sought immediately , often sign destabilization chronic obstructive pulmonary disease . circumstances , therapeutic regimen re-evaluated additional therapeutic options considered . compatibility ( physical chemical ) , efficacy , safety formoterol fumarate inhalation solution mixed drugs nebulizer established .",
        "doid_entities": [
            {
                "text": "chronic obstructive pulmonary disease (DOID:3083)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3083"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "formoterol fumarate inhalation solution , 20 mcg/2 ml supplied clear , colorless sterile solution nebulization 2.5 ml low-density polyethylene unit dose vials . vial overwrapped foil pouch supplied cartons listed . carton 30 individually wrapped unit dose vials , ndc 76204-030-01 carton 60 individually wrapped unit dose vials , ndc 76204-030-02 storage handling : prior dispensing patient : store refrigerator , 2\u00b0c 8\u00b0c ( 36\u00b0f 46\u00b0f ) . protect pouch light heat . dispensing patient : store refrigerator 2\u00b0c 8\u00b0c ( 36\u00b0f 46\u00b0f ) discard expires store room temperature , 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) discard used 3 months . protect pouch light heat . formoterol fumarate inhalation solution administered via standard jet nebulizer connected air compressor adequate airflow equipped facemask mouthpiece . vial always stored foil pouch , removed immediately . take mouth . contents partially used container discarded . discard container top . keep reach children",
    "adverseReactions": "laba , including formoterol fumarate inhalation solution , without inhaled corticosteroid contraindicated patients asthma [ ( 5.1 ) ] . formoterol fumarate inhalation solution indicated treatment asthma .",
    "indications_original": "Formoterol Fumarate Inhalation Solution\u00a0is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ( 1.1 ) Important limitations of use: Formoterol Fumarate Inhalation Solution\u00a0is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ( 1.2 , 5.2 ) Formoterol Fumarate Inhalation Solution\u00a0is not indicated to treat asthma. ( 1.2 )",
    "contraindications_original": "The recommended dose of Formoterol Fumarate Inhalation Solution is one 20 mcg unit-dose vial administered twice daily (morning and evening) by nebulization. A total daily dose greater than 40 mcg is not recommended.\n                  Formoterol Fumarate Inhalation Solution should be administered by the orally inhaled route via a standard jet nebulizer connected to an air compressor. The safety and efficacy of Formoterol Fumarate Inhalation Solution have been established in clinical trials when administered using the PARI-LC Plus\u00ae nebulizer (with a facemask or mouthpiece) and the PRONEB\u00ae Ultra compressor. The safety and efficacy of Formoterol Fumarate Inhalation Solution delivered from non-compressor based nebulizer systems have not been established.\n                  Formoterol Fumarate Inhalation Solution should always be stored in the foil pouch, and only removed IMMEDIATELY BEFORE USE. Contents of any partially used container should be discarded.\n                  If the recommended maintenance treatment regimen fails to provide the usual response, medical advice should be sought immediately, as this is often a sign of destabilization of COPD. Under these circumstances, the therapeutic regimen should be re-evaluated and additional therapeutic options should be considered.\n                  The drug compatibility (physical and chemical), efficacy, and safety of Formoterol Fumarate Inhalation Solution when mixed with other drugs in a nebulizer have not been established.",
    "warningsAndPrecautions_original": "Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL is supplied as a clear, colorless sterile solution for nebulization in 2.5 mL low-density polyethylene unit dose vials. Each vial is overwrapped in a foil pouch and supplied in cartons as listed below.\n                  Carton of 30 individually wrapped unit dose vials,\n \n  NDC 76204-030-01\n                  \n                  Carton of 60 individually wrapped unit dose vials,\n \n  NDC 76204-030-02\n                  \n                  \n                     Storage and Handling:\n                  \n                  \n                     \n                        Prior to dispensing to the patient:\n \n  Store in a refrigerator, 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F). Protect pouch from light and heat.\n\n \n                  \n                     \n                        After dispensing to the patient:\n                     \u00a0Store in a refrigerator at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F) and discard when drug expires or store at room temperature, 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F) and discard if not used after 3 months. Protect pouch from light and heat.\n\n \n                  \n                     Formoterol Fumarate Inhalation Solution should only be administered via a standard jet nebulizer connected to an air compressor with an adequate airflow and equipped with a facemask or mouthpiece.\n                     Vial should always be stored in the foil pouch, and only removed IMMEDIATELY before use.\n                     Do not take by mouth.\n                     Contents of any partially used container should be discarded.\n                     Discard the container and top after use.\n                     Keep out of the reach of children",
    "adverseReactions_original": "Use of a LABA, including Formoterol Fumarate Inhalation Solution, without an inhaled corticosteroid is contraindicated in patients with asthma\n \n  [see WARNINGS and PRECAUTIONS (5.1)]. Formoterol Fumarate Inhalation Solution is not indicated for the treatment of asthma.",
    "drug": [
        {
            "name": "Formoterol Fumarate Inhalation Solution",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5147"
        }
    ]
}